- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc stock price live, this page displays NASDAQ ALLO stock exchange data. View the ALLO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Allogene Therapeutics Inc real time stock price chart below.
What Is the Allogene Therapeutics Inc Stock Price Today?
The Allogene Therapeutics Inc stock price today is 1.070.
What Is the Stock Symbol for Allogene Therapeutics Inc?
The stock symbol for Allogene Therapeutics Inc is ""ALLO.""
What Stock Exchange Does Allogene Therapeutics Inc Trade On?
Allogene Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Allogene Therapeutics Inc a Good Stock to Buy?
Determining whether Allogene Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALLO quote. (ISIN: US0197701065)
What Is the Allogene Therapeutics Inc Stock Price Today?
The Allogene Therapeutics Inc stock price today is 1.070.
What Is the Stock Symbol for Allogene Therapeutics Inc?
The stock symbol for Allogene Therapeutics Inc is ""ALLO.""
What Stock Exchange Does Allogene Therapeutics Inc Trade On?
Allogene Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Allogene Therapeutics Inc a Good Stock to Buy?
Determining whether Allogene Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALLO quote. (ISIN: US0197701065)
Fair Value
An estimate of a Allogene Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.990
1.085
52 wk Range
0.862
3.780
ALLO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
1/2
Fair Value
An estimate of a Allogene Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9901.085
52 wk Range
0.8623.780
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALLO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Allogene Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
7.850
Upside
+633.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Allogene Therapeutics Inc For: 13 August
- Investing.com
- Form 8K Allogene Therapeutics Inc For: 13 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Allogene Therapeutics Inc Company Profile
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics Inc SWOT Analysis
Innovative Therapies | Allogene's allogeneic CAR T-cell therapies show promise in oncology, with ALLO-316 demonstrating encouraging results in renal cell carcinoma treatment |
Clinical Challenges | Explore the impact of trial delays on Allogene's market position, including postponed milestones for the ALPHA3 trial and extended timelines for key programs |
Financial Outlook | Analysts project zero revenue for 2025-2026, with $53.2M expected in 2027. Price targets range from $5 to $14, with a consensus "Buy" recommendation |
Strategic Positioning | Delve into Allogene's focus on early-line oncology and potential in addressing unmet needs in RCC and NHL, balancing innovation against competitive pressures |
Allogene Therapeutics Inc Earnings Call Summary for Q2/2025
- Q2 2025 net loss of $50.9M ($0.23/share), beating expectations; stock rose 2.91% after hours to $1.06
- Cash position strong at $302.6M; company projects runway into 2027 with expected 2025 cash burn of ~$150M
- Advancing CAR T therapies; focus on reducing lymphodepletion in treatment protocols
- Full-year GAAP operating expenses projected at ~$230M; MRD conversion rates to be shared at interim analysis
- CEO highlights diverse clinical pipeline; CMO emphasizes bold steps in immune-mediated condition treatments
Last Updated: 13/08/2025, 23:04
Read Full TranscriptCompare ALLO to Peers and Sector
Metrics to compare | ALLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALLOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −0.5x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 0.7x | 2.6x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.3x | |
Upside (Analyst Target) | - | 193.5% | 40.3% | |
Fair Value Upside | Unlock | 15.6% | 4.7% | Unlock |
Analyst Ratings
11 Buy
3 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.850
(+633.64% Upside)
Earnings
Latest Release
Aug 13, 2025
EPS / Forecast
-0.23 / -0.27
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Allogene Therapeutics Trade On?
Allogene Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Allogene Therapeutics?
The stock symbol for Allogene Therapeutics is "ALLO."
What Is the Allogene Therapeutics Market Cap?
As of today, Allogene Therapeutics market cap is 230.76M.
What Is Allogene Therapeutics's Earnings Per Share (TTM)?
The Allogene Therapeutics EPS (TTM) is -1.22.
When Is the Next Allogene Therapeutics Earnings Date?
Allogene Therapeutics will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is ALLO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Allogene Therapeutics Stock Split?
Allogene Therapeutics has split 0 times.
How Many Employees Does Allogene Therapeutics Have?
Allogene Therapeutics has 228 employees.
What is the current trading status of Allogene Therapeutics (ALLO)?
As of 14 Aug 2025, Allogene Therapeutics (ALLO) is trading at a price of 1.07, with a previous close of 1.04. The stock has fluctuated within a day range of 0.99 to 1.09, while its 52-week range spans from 0.86 to 3.78.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.